Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Q1 2026 Earnings Presentation
8 slides from Clearpoint Neuro's earnings presentation, May 13, 2026
Slide 1: ClearPoint Neuro Reports First Quarter 2026 Results
May 13, 2026 ClearPoint Neuro Reports First Quarter 2026 Results Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-en
Slide 2: CEO Commentary, Business Outlook and Quarterly Results
"Our team is off to a strong start in 2026 with forward progress across our entire four-pillar growth strategy," commented Joe Burnett, President and CEO at ClearPoint Neuro. "While record revenue achievement and 25% organic devices growth made the headline, there is no shortage of meaningful strate
Slide 3: Gross Margin, Operating Expenses and Cash Position
The Company achieved a gross margin of 64% on its sales for the three months ended March 31, 2026, and a gross margin of 60% in the same period in 2025. The increase in gross margin is primarily due to lower excess and obsolete inventory for the three months ended March 31, 2026, as compared to the
Slide 4: Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future perfor
Slide 5: Forward-Looking Statements Risks (continued)
the Company's other business operations; the possibility that the anticipated benefits of the IRRAS transaction are not realized when expected or at all; the Company's failure to integrate IRRAS into its business in accordance with expectations; deviations from the expected market potential of the I
Slide 6: Consolidated Statements of Operations
For the Three Months Ended March 31, 2026 2025 Revenue: Product revenue $ 8,802 $ 5,291 Service and other revenue 3,326 3,194 Total revenue 12,128 8,485 Cost of revenue 4,372 3,353 Gross profit 7,756 5,132 Research and development costs 4,522 3,379 Sales and marketing expenses 6,715 3,834 General an
Slide 7: Consolidated Balance Sheets
March 31, December 2026 31, (Unaudited) 2025 ASSETS Current assets: Cash and cash equivalents $ 35,593 $ 45,923 Accounts receivable, net 8,662 6,549 Inventory, net 8,573 8,359 Prepaid expenses and other current assets 2,049 2,769 Total current assets 54,877 63,600 Property and equipment, net 2,914 2
Slide 8: Consolidated Statements of Cash Flows
Three Months Ended March 31, 2026 2025 Cash flows from operating activities: Net loss $ (9,552 ) $ (6,026 ) Adjustments to reconcile net loss to net cash flows from operating activities: Allowance for credit losses (recoveries) (95 ) 217 Depreciation and amortization 86 103 Amortization of intangibl